Non-Communicable Chronic DiseasesNCT05122832
Prevalence of NCD Risk Factors in Kazakhstan
An observational study of Non-Communicable Chronic Diseases, run by Asfendiyarov Kazakh National Medical University at 1 site in Kazakhstan.
Trial summary
This is a cross-sectional study that aims to study the prevalence of risk factors of noncommunicable diseases in people aged 18 to 69 years using the standardized and adopted STEPS questionnaire in the Republic of Kazakhstan. Read more about this study
- Who is it for?
- Ages 18 to 69 years
- Conditions the study is for
- Non-Communicable Chronic Diseases
- What is being tested?
- Blood test, STEPwise Approach to NCD Risk Factor Surveillance (STEPS) and Spirometry
- Type of treatment
- Pill or oral medicine
- How many people
- 20,400 participants
- Where
- 1 siteKazakhstan
- Study dates
- 23 Oct 2021to 20 Aug 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 69 years
- All sexes
- Adult, Older adult
Study population: All ethnic groups in Kazakhstan
Who may be able to join
- Age Limits 18-69 years
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Preventive and Personalized Medicine (2021-2023)
This is a cross-sectional study that aims to study the prevalence of risk factors of noncommunicable diseases in people aged 18 to 69 years using the standardized and adopted STEPS questionnaire in the Republic of Kazakhstan.
Read the detailed description
The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids.
- Conditions
- Non-Communicable Chronic Diseases
- Being tested
- Blood test, STEPwise Approach to NCD Risk Factor Surveillance (STEPS), Spirometry
- Medical subject headings
- Noncommunicable Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood testDiagnostic test
Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
STEPwise Approach to NCD Risk Factor Surveillance (STEPS)Diagnostic test
The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
SpirometryDiagnostic test
Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
| Study group | Role | What they receive |
|---|---|---|
| The study Group | Population of Kazakhstan Receives: Diagnostic Test: Blood test; Diagnostic Test: STEPwise Approach to NCD Risk Factor Surveillance (STEPS); Diagnostic Test: Spirometry |
What is being measured
The primary outcome is the main question the study is designed to answer.
tobacco use
currently smoke tobacco, currently smoke tobacco daily, age started smoking, daily smokers smoking manufactured cigarettes
Measured: 1 year
alcohol consumption
lifetime abstainers, past 12 month abstainers, currently drink (drank alcohol in the past 30 days), heavy episodic drinking (6 or more drinks on any occasion in the past 30 days).
Measured: 1 year
physical activity
insufficient physical activity (defined as < 150 minutes of moderate-intensity activity per week, or equivalent), physical activity on average per day (minutes), not engaging in vigorous activity.
Measured: 1 year
unhealthy diet
days fruit consumed in a typical week, servings of fruit consumed on average per day, days vegetables consumed in a typical week, servings of vegetables consumed on average per day, less than 5 servings of fruit and/or vegetables on average per day, always or often add salt or salty sauce to their food before eating or as they are eating, always or often eat processed foods high in salt.
Measured: 1 year
BMI
overweight (BMI ≥ 25 kg/m2), obese (BMI ≥ 30 kg/m2), normal weight
Measured: 1 year
raised blood pressure
systolic blood pressure - SBP (mmHg), including those currently on medication for raised BP, diastolic blood pressure - DBP (mmHg), including those currently on medication for raised BP, raised BP (SBP ≥ 140 and/or DBP ≥ 90 mmHg or currently on medication for raised BP), raised BP (SBP ≥ 140 and/or DBP ≥ 90 mmHg or currently on medication for raised BP) who are not currently on medication for raised BP.
Measured: 1 year
raised blood glucose
fasting blood glucose, including those currently on medication for raised blood glucose, impaired fasting glycaemia (plasma venous value ≥6.1 mmol/L (110 mg/dl) and <7.0 mmol/L (126 mg/dl)), raised fasting blood glucose (plasma venous value ≥ 7.0 mmol/L (126 mg/dl)) or currently on medication for raised blood glucose.
Measured: 1 year
abnormal blood lipids
total blood cholesterol, including those currently on medication for raised cholesterol, raised total cholesterol,
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2021
- Study start23 Oct 2021
- Primary completion20 Aug 2022
- Study completion20 Aug 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Non-Communicable Chronic DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 20,400 participants (actual)
Sponsor and investigators
- Lead sponsor
- Asfendiyarov Kazakh National Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ildar Fakhradiyev, Asfendiyarov Kazakh National Medical University
- Investigators
- Timur M Saliev, Principal investigator, S.D. Asfendiyarov Kazakh National Medical UniversityIldar Fakhradiyev, PhD, Study chair, S.D. Asfendiyarov Kazakh National Medical UniversityMukhtar B Kulimbet, MD/MSc, Study director, S.D. Asfendiyarov Kazakh National Medical UniversityZhumaly A Kauyzbay, PhD, AP, Principal investigator, Joint Stock Company - South Kazakhstan Medical AcademySamat S Saparbayev, PhD, Principal investigator, West Kazakhstan Marat Ospanov Medical UniversityAlma U Nurtazina, MD/PhD, Principal investigator, NCJSC Semey Medical UniversityBayan A Ainabekova, MD/DMSc, Principal investigator, NCJSC Astana Medical UniversityAnar A Turmukhambetova, DMSc, Principal investigator, NCJSC Karaganda Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05122832
- Sponsor's protocol ID
- 1197
- Status last verified
- Mar 2023
- First submitted
- 29 Sep 2021
- Last updated
- 14 Mar 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Baspakova A, Abitova AZ, Mussin NM, Kaliyev AA, Yerimbetova G, Zhumagaliyeva S, Ashimova Z, Zhilisbayeva KR, Umbetova AA, Nurtazina AU, Tamadon A. Sex differentials in the prevalence of behavioral risk factors and non-communicable diseases in adult populations of West Kazakhstan. Front Public Health. 2024 Feb 14;12:1333887. doi: 10.3389/fpubh.2024.1333887. eCollection 2024.
PubMed 38420037Nursultanova L, Kabulbayev K, Ospanova D, Tazhiyeva A, Datkhayev U, Saliev T, Tanabayeva S, Fakhradiyev I. Prevalence of chronic kidney disease in Kazakhstan: evidence from a national cross-sectional study. Sci Rep. 2023 Sep 7;13(1):14710. doi: 10.1038/s41598-023-42031-2.
PubMed 37679536
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Preventive and Personalized Medicine (2021-2023)
- ClinicalTrials.gov ID
- NCT05122832
- Acronym / sponsor ID
- 1197
- Conditions
- Non-Communicable Chronic Diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20,400 participants (actual)
- Lead sponsor
- Asfendiyarov Kazakh National Medical UniversityUniversity, hospital or other
- Study start
- 23 Oct 2021 (actual)
- Primary completion
- 20 Aug 2022 (actual)
- Study completion
- 20 Aug 2022 (actual)
- First posted
- 17 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a cross-sectional study that aims to study the prevalence of risk factors of noncommunicable diseases in people aged 18 to 69 years using the standardized and adopted STEPS questionnaire in the Republic of Kazakhstan.
Detailed description
The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The study Group | – | Diagnostic Test: Blood test, Diagnostic Test: STEPwise Approach to NCD Risk Factor Surveillance (STEPS), Diagnostic Test: SpirometryPopulation of Kazakhstan |
Who may qualify
- Ages
- 18 to 69 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All ethnic groups in Kazakhstan
Key inclusion criteria (1 listed)
- Age Limits 18-69 years
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood testGlucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott) | Diagnostic test | The study Group |
| STEPwise Approach to NCD Risk Factor Surveillance (STEPS)The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety. | Diagnostic test | The study Group |
| SpirometrySpirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale. | Diagnostic test | The study Group |
Primary outcome
tobacco use
Time frame: 1 year
currently smoke tobacco, currently smoke tobacco daily, age started smoking, daily smokers smoking manufactured cigarettes
alcohol consumption
Time frame: 1 year
lifetime abstainers, past 12 month abstainers, currently drink (drank alcohol in the past 30 days), heavy episodic drinking (6 or more drinks on any occasion in the past 30 days).
physical activity
Time frame: 1 year
insufficient physical activity (defined as < 150 minutes of moderate-intensity activity per week, or equivalent), physical activity on average per day (minutes), not engaging in vigorous activity.
unhealthy diet
Time frame: 1 year
days fruit consumed in a typical week, servings of fruit consumed on average per day, days vegetables consumed in a typical week, servings of vegetables consumed on average per day, less than 5 servings of fruit and/or vegetables on average per day, always or often add salt or salty sauce to their food before eating or as they are eating, always or often eat processed foods high in salt.
BMI
Time frame: 1 year
overweight (BMI ≥ 25 kg/m2), obese (BMI ≥ 30 kg/m2), normal weight
raised blood pressure
Time frame: 1 year
systolic blood pressure - SBP (mmHg), including those currently on medication for raised BP, diastolic blood pressure - DBP (mmHg), including those currently on medication for raised BP, raised BP (SBP ≥ 140 and/or DBP ≥ 90 mmHg or currently on medication for raised BP), raised BP (SBP ≥ 140 and/or DBP ≥ 90 mmHg or currently on medication for raised BP) who are not currently on medication for raised BP.
raised blood glucose
Time frame: 1 year
fasting blood glucose, including those currently on medication for raised blood glucose, impaired fasting glycaemia (plasma venous value ≥6.1 mmol/L (110 mg/dl) and <7.0 mmol/L (126 mg/dl)), raised fasting blood glucose (plasma venous value ≥ 7.0 mmol/L (126 mg/dl)) or currently on medication for raised blood glucose.
abnormal blood lipids
Time frame: 1 year
total blood cholesterol, including those currently on medication for raised cholesterol, raised total cholesterol,
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2023.
- Derived from this study: PubMed 38420037Baspakova A, Abitova AZ, Mussin NM, Kaliyev AA, Yerimbetova G, Zhumagaliyeva S, Ashimova Z, Zhilisbayeva KR, Umbetova AA, Nurtazina AU, Tamadon A. Sex differentials in the prevalence of behavioral risk factors and non-communicable diseases in adult populations of West Kazakhstan. Front Public Health. 2024 Feb 14;12:1333887. doi: 10.3389/fpubh.2024.1333887. eCollection 2024.
- Derived from this study: PubMed 37679536Nursultanova L, Kabulbayev K, Ospanova D, Tazhiyeva A, Datkhayev U, Saliev T, Tanabayeva S, Fakhradiyev I. Prevalence of chronic kidney disease in Kazakhstan: evidence from a national cross-sectional study. Sci Rep. 2023 Sep 7;13(1):14710. doi: 10.1038/s41598-023-42031-2.
Related trials for Non-Communicable Chronic Diseases
RecruitingObservational study
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Chronic Liver Disease and Cirrhosis, Liver Cancer
RecruitingObservational study
CytOSorb TreatMent Of Critically Ill PatientS Registry
Septic Shock, Acute Respiratory Distress Syndrome
RecruitingObservational study
Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data
Non-communicable Diseases (NCD), Neoplams
RecruitingObservational study
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease
Not yet recruitingObservational study
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness
Liver Fibrosis, Liver Cirrhosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Timur M Saliev principal investigator
S.D. Asfendiyarov Kazakh National Medical University
Ildar Fakhradiyev, PhD study chair
S.D. Asfendiyarov Kazakh National Medical University
Mukhtar B Kulimbet, MD/MSc study director
S.D. Asfendiyarov Kazakh National Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-Communicable Chronic Diseases, run by Asfendiyarov Kazakh National Medical University at 1 site in Kazakhstan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
tobacco use (time frame: 1 year). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05122832, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2023.